Imagine a smart shield for pigs that doesn't just block a deadly virus, but also lets vets tell if a pig was vaccinated or actually sick. Instead of using old-school weakened viruses that can be risky, this uses a new design to keep animals safe. It's like upgrading from a basic lock to a high-tech security system that works across different versions of the virus.
African Swine Fever causes massive economic losses, and current live attenuated vaccines are often unsafe or cannot be distinguished from natural infections during surveillance.
A vaccine platform producing candidates with limited replication capacity and a set of DIVA diagnostic tests to tell vaccinated animals apart from infected ones.
If you are a vaccine manufacturer dealing with the safety risks of live attenuated vaccines — this project developed a platform for candidates with limited replication capacity that provides protection against diverse ASFV variants. This allows for the production of safer, more effective biological products.
If you are a farm owner dealing with unpredictable virus outbreaks — this project developed DIVA diagnostic tests that distinguish vaccinated animals from infected ones. This enables precise disease monitoring and more effective control strategies to protect your herd.
If you are a policy maker dealing with virus transmission between wild boar and domestic pigs — this project developed mathematical epidemiology models. These tools help design innovative management policies to protect the global economy from ASF impacts.
Based on available project data, there is no specific pricing or unit cost mentioned for the vaccine candidates.
The project has established molecular and cellular tools for production and purification, but it is currently in the stage of optimizing vaccine candidates.
Based on available project data, specific IP and licensing agreements are not detailed, though the project is coordinated by Laboratorios Hipra SA.
It integrates via DIVA (Differentiating Infected from Vaccinated Animals) tests, allowing authorities to monitor disease spread even in vaccinated populations.
The project period runs from 2024-01-01 to 2027-12-31, suggesting the development phase continues through late 2027.
The project is heavily industry-weighted with 7 industrial partners (37% ratio), including a specialized SME presence. Led by Laboratorios Hipra SA, the 19-partner group spans 11 countries across Europe, the USA, and Kenya, combining academic research (4 universities, 6 research centers) with commercial production capabilities to ensure the transition from lab to market.
Contact Laboratorios Hipra SA in Spain
Contact us to track the commercialization of these ASFV vaccine candidates.
